Early and Late Complications of COVID-19

Characteristics and Predictors of Early and Late Cardiovascular Complications of Covid-19 Patients - the PoLoCOV-Study (Polish LONG-COVID Cardiovascular Study)

Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2). Unfortunately, COVID-19 is not only a short-term infection. Patients (pts) recovering from SARS-COV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome and as well as many other complications.

The vast majority of COVID-19 patients remaining in isolation/quarantine, due to the mild course of the disease, do not require hospitalization. In this group of patients, the course of COVID-19 is very different - from asymptomatic patients to very severe and long lasting symptoms also with a decrease in saturation.

There are many studies describing the course and complications of patients hospitalized due to COVID-19. There is little published data on how non-hospitalized patients get sick and what are the early and late complications of SARS-CoV-2 infection. In addition, many patients remain ill even many months after COVID-19, entering what is known as LONG-COVID.

Therefore, the STOP-COVID Registry was established. The purpose of the Registry is to assess the course of COVID-19 infection, early and late cardiovascular complications of COVID-19 in patients with and without hospitalization. In addition, the purpose of the STOP-COVID Registry is to assess the incidence of LONG-COVID with all other complications and to identify predictive factors.

Study Overview

• Status: Active, not recruiting
• Conditions: Covid19; LONG-COVID

Detailed Description

The following patients are included in the Registry: Patients 18 years and older diagnosed with COVID-19, in accordance with the current guidelines of the Ministry of Health of Poland, after full recovery (resolution of clinical symptoms, minimum 14 days after last symptoms). The Registry includes patients with and without hospitalization .

Approval from the Bioethics Committee of Lodz Regional Medical Chamber to conduct the Registry was obtained.

The Registry was held at the: Saint Family Hospital Medical Center, Lodz, Poland Patient information, course of the disease, post-COVID-19 complaints, comorbidities and current treatment were collected at visit "0" within 4-8 weeks after the end of COVID-19.

Subsequently, patients were ordered the following tests:

• 12-lead ECG
• 24-hour Holter ECG monitoring
• 24-hour Holter blood pressure monitoring
• Echocardiographic of the Heart assessment
• Biochemical tests: Lipid Profile (total cholesterol, LDL fraction, HDL, triglycerides), glucose or glycosylated hemoglobin (HbA1c) level, D-dimers.

In patients with indications, the following were additionally performed: MRI of the heart, Angio CT of pulmonary vessels, Angio CT of coronary vessels or other diagnostic tests. Depending on the indications of the pts, they were referred for other tests and specialist consultations. All pts were diagnosed and treated in accordance with the current recommendations of the European Cardiology Society (ESC) and Polish Cardiac Society (PCS).

If any abnormalities were found, patients were treated in accordance with the current ESC guidelines. In the event of complications after COVID-19, each patient will be treated in accordance with current guidelines and recommendations, in accordance with current medical knowledge.

After a period of 3 months after COVID-19, new symptoms that appeared after COVID-19, remained and/or worsened after COVID-19 were assessed at the follow-up visit, based on the patient's interview. If such symptoms occurred, patients were classified as LONG-COVID. Symptoms that may have resulted from the severity of the underlying condition were not classified as LONG-COVID.

Patients with LONG-COVID, after excluding complications/contraindications, will be referred to the post-COVID rehabilitation program. This program covers a comprehensive range of rehabilitation with dietary and psychological consultations. Patients referred to the rehabilitation program will constitute the REHA-STOP-COVID group. The rehabilitation program will last 6 weeks. At the beginning and at the end of the program, each patient will have fitness assessment performed with the following tests:

• oxygen saturation assessment performed with a pulse oximeter;
• physical capacity assessment with 6 minute walking test (6MWT)
• Dyspnea assessment with modified 0-10 Borg scale
• Fatigue assessment with Modified Fatigue Impact Scale (MFIS)
• Muscle Strength Assessment
• lower extremity function and mobility with Short Physical Performance Battery test (SPPB)

Annual reassessment of all patients is planned for 5 years after COVID-19.

During the control visits, patients will be ordered the following:

• Clinical evaluation with health assessment, comorbidities and symptoms that may be due to a history of COVID-19
• 12-lead ECG
• 24-hour Holter ECG monitoring
• 24-hour Holter blood pressure monitoring
• Echocardiographic of the Heart assessment
• Biochemical tests: Lipid Profile (total cholesterol, LDL fraction, HDL, triglycerides), glucose or glycosylated hemoglobin (HbA1c).

Additionally, a questionnaire will be completed by the patient with an assessment of his/her health, weight, height, BMI, risk factors for cardiovascular diseases (smoking, alcohol abuse), physical activity, all medications that the patient takes, whether the patient was re-infected with SARS-CoV in the past years (date) , whether the patient was vaccinated (with full vaccination date).

Each patient from the STOP-COVID program, in the event of deterioration of health and / or the appearance of new ailments, may be referred for the consultation to the Saint Family Hospital Medical Center by a GP and/or another specialist during the whole period of the study.

During the entire study period, the following will be registered in the medical database:

1. Any new medical event assessed by 2 doctors as a complication after COVID-19
2. Any hospitalization related to complications of COVID-19 as well as any other reason
3. Each severity has already been diseases diagnosed and treated, with information whether it required correction / modification of the current treatment
4. Any newly diagnosed diseases
5. Any abnormalities in the results of diagnostic examinations, laboratory tests and consultations

• Study Type: Observational
• Enrollment (Actual): 1900

Contacts and Locations

Study Locations

• Poland
  • Łódź, Poland, 90-302
    • Medical Center, Saint Family Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients 18 years and older diagnosed with COVID-19, after full recovery (resolution of clinical symptoms, minimum 14 days after last symptoms), with and without hospitalization .

Description

Inclusion Criteria:

Patients after COVID-19, 18 years and older

Exclusion Criteria:

None

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Early and Late COVID-19 cardio-vascular complications	Early and Late COVID-19 cardio-vascular complications	5 years
Predictors of Long-Covid Cardio-Vascular complications	Predictors of Long-Covid Cardio-Vascular complications	5 years
SCORE - algorithm to help to predict the highest risk of Long-Covid complications	SCORE - algorithm to help to predict the highest risk of Long-Covid complications	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Detailed patients' characteristics and differences in those with and without Long-Covid complications	Detailed patients' characteristics and differences in those with and without Long-Covid	5 years
Definition and characteristics of the early and Late COVID-19 complications	Definition and characteristics of the early and Late COVID-19 complications	5 years
Comparison of complications and Long-Covid depending on the severity of the course of COVID-19 COVID-19, comorbidities	Comparison of complications and Long-Covid depending on the severity of the course of COVID	5 years

Collaborators and Investigators

• Sponsor: Michal Chudzik

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): May 29, 2020
• Primary Completion (Anticipated): September 30, 2022
• Study Completion (Anticipated): September 30, 2022

Study Registration Dates

• First Submitted: August 23, 2021
• First Submitted That Met QC Criteria: August 23, 2021
• First Posted (Actual): August 24, 2021

Study Record Updates

• Last Update Posted (Actual): August 24, 2021
• Last Update Submitted That Met QC Criteria: August 23, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Covid19; Chronic Fatigue Syndrome; Covid complications; Long-Covid
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: Stop-Covid/1/2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No